Inoue, Noriyuki
Dr. Noriyuki Inoue graduated from University of Tsukuba with a Master’s degree in 2002. After graduation, he entered at Tokyo New Drug Research Laboratories, Kowa company, Ltd. Thereafter, he was on loan to the laboratory of Prof. Nobuhiro Yamada and Prof. Hitoshi Shimano in University of Tsukuba. He studied on dyslipidemia, obesity, hypertension and diabetes for 4 years. He investigated lipid synthesis transcription factor SREBP, especially relation between SREBP and p21WAF1/CIP1. Additionally, He revealed and p21WAF1/CIP1 had an important role for obesity and insulin resistance.He could reveal thedirect interaction with lipid synthesis and cell growth, and establish the new concept that metabolic disorder might be associated with cell growth protein. Thorough these works, he could publish some papers and gain doctoral degree.
At his company, he could establish the methods of insulin secretion screening system in some kinds of insulin secreted cell line. He has evaluated the treatment effects of anti-diabetes compounds using type 2 diabetic models, ob/ob, db/db, KKAy, diet-induced obesity mice and ZDF rats or so. He has kept researching the therapy drugs for metabolic disorder, especially diabetes over ten years.
He joined CICS in March, 2013. He has kept focusing on Diabetes field for new anti-diabetic drugs in CICS.
Publications
Show
Iwata H, Goettsch C, Sharma A, Ricchiuto P, Goh WW, Halu A, Yamada I, Yoshida H, Hara T, Wei M, Inoue N, Fukuda D, Mojcher A, Mattson PC, Barabási AL, Boothby M, Aikawa E, Singh SA, Aikawa M
PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation.
Yamamoto T, Watanabe K, Inoue N, Nakagawa Y, Ishigaki N, Matsuzaka T, Takeuchi Y, Kobayashi K, Yatoh S, Takahashi A, Suzuki H, Yahagi N, Gotoda T, Yamada N, Shimano H
Protein kinase Cbeta mediates hepatic induction of sterol-regulatory element binding protein-1c by insulin.
Ishikawa M, Iwasaki Y, Yatoh S, Kato T, Kumadaki S, Inoue N, Yamamoto T, Matsuzaka T, Nakagawa Y, Yahagi N, Kobayashi K, Takahashi A, Yamada N, Shimano H
Cholesterol accumulation and diabetes in pancreatic beta-cell-specific SREBP-2 transgenic mice: a new model for lipotoxicity.
Inoue N, Yahagi N, Yamamoto T, Ishikawa M, Watanabe K, Matsuzaka T, Nakagawa Y, Takeuchi Y, Kobayashi K, Takahashi A, Suzuki H, Hasty AH, Toyoshima H, Yamada N, Shimano H
Cyclin-dependent kinase inhibitor, p21WAF1/CIP1, is involved in adipocyte differentiation and hypertrophy, linking to obesity, and insulin resistance.
Matsuzaka T, Shimano H, Yahagi N, Kato T, Atsumi A, Yamamoto T, Inoue N, Ishikawa M, Okada S, Ishigaki N, Iwasaki H, Iwasaki Y, Karasawa T, Kumadaki S, Matsui T, Sekiya M, Ohashi K, Hasty AH, Nakagawa Y, Takahashi A, Suzuki H, Yatoh S, Sone H, Toyoshima H, Osuga J, Yamada N
Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance.
Nakakuki M, Shimano H, Inoue N, Tamura M, Matsuzaka T, Nakagawa Y, Yahagi N, Toyoshima H, Sato R, Yamada N
A transcription factor of lipid synthesis, sterol regulatory element-binding protein (SREBP)-1a causes G(1) cell-cycle arrest after accumulation of cyclin-dependent kinase (cdk) inhibitors.
Okada S, Kobayashi K, Ishikawa M, Inoue N, Yamada N, Shimano H
Abdominal Irradiation Ameliorates Obesity in ob/ob Mice.
Ishikawa M, Okajima F, Inoue N, Motomura K, Kato T, Takahashi A, Oikawa S, Yamada N, Shimano H
Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells.
Ishikawa M, Okajima F, Inoue N, Motomura K, Kato T, Takahashi A, Oikawa S, Yamada N, Shimano H
Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells.
Nakagawa Y, Shimano H, Yoshikawa T, Ide T, Tamura M, Furusawa M, Yamamoto T, Inoue N, Matsuzaka T, Takahashi A, Hasty AH, Suzuki H, Sone H, Toyoshima H, Yahagi N, Yamada N
TFE3 transcriptionally activates hepatic IRS-2, participates in insulin signaling and ameliorates diabetes.
Inoue N, Shimano H, Nakakuki M, Matsuzaka T, Nakagawa Y, Yamamoto T, Sato R, Takahashi A, Sone H, Yahagi N, Suzuki H, Toyoshima H, Yamada N
Lipid synthetic transcription factor SREBP-1a activates p21WAF1/CIP1, a universal cyclin-dependent kinase inhibitor.
Yahagi N, Shimano H, Matsuzaka T, Sekiya M, Najima Y, Okazaki S, Okazaki H, Tamura Y, Iizuka Y, Inoue N, Nakagawa Y, Takeuchi Y, Ohashi K, Harada K, Gotoda T, Nagai R, Kadowaki T, Ishibashi S, Osuga J, Yamada N
p53 involvement in the pathogenesis of fatty liver disease.
Sone H, Shimano H, Sakakura Y, Inoue N, Amemiya-Kudo M, Yahagi N, Osawa M, Suzuki H, Yokoo T, Takahashi A, Iida K, Toyoshima H, Iwama A, Yamada N
Acetyl-coenzyme A synthetase is a lipogenic enzyme controlled by SREBP-1 and energy status.
Sone H, Sakauchi M, Takahashi A, Suzuki H, Inoue N, Iida K, Shimano H, Toyoshima H, Kawakami Y, Okuda Y, Matsuo K, Yamada N
Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity.
Sakakura Y, Shimano H, Sone H, Takahashi A, Inoue N, Toyoshima H, Suzuki S, Yamada N, Inoue K
Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis.